The combination of Xindilimumab and albumin bound paclitaxel in the treatment of stage IB-IIIB NSCLC can improve the patient’s overall health status, enhance their quality of life, and not increase adverse reactions. The gene discussed is ALB; the disease is non-small cell lung carcinoma.